HAE

Haemonetics Corp. 10-Q Summary: Quarter Ended June 30, 2001

Business Context and Reporting Period

Haemonetics Corporation designs, manufactures, and markets automated blood processing systems, including blood bank, red cell, surgical, and plasma collection products. This report covers the three-month period ended June 30, 2001 (First Quarter of Fiscal Year 2002). The company operates globally, with approximately 62% of revenues generated outside the United States.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net revenues increased 7.9% year-over-year, driven by an 11.3% increase in disposable sales. Constant currency revenue growth was 8.6%.
• Product Mix: Significant growth was seen in Red Cell disposables (+52.2% constant currency), Plasma disposables (+28.4%), and Surgical disposables (+11.5%). This was offset by a 25.7% decline in equipment revenues due to a strategic shift toward placing company-owned equipment on loan rather than selling it.
• Profitability: Operating income increased 21.5% to $9.5 million. Gross margin improved slightly to 47.9%.
• Accounting Changes: Net income includes a one-time cumulative effect of a change in accounting principle of $2.3 million (net of tax) related to the adoption of SFAS No. 133 (Derivatives). Additionally, the company adopted SFAS No. 142, ceasing goodwill amortization, which increased other income.
• Cash Flow: Operating cash flow decreased to $1.5 million from $4.5 million in the prior year, primarily due to increased inventory levels ($4.6 million increase) and higher accounts receivable ($2.2 million increase).

Guidance, Outlook, and Risks

Management Commentary: Management attributes revenue growth to volume increases in the U.S. market for Red Cell and Surgical products, as well as an upturn in plasma collections. The company continues to invest in R&D ($4.8 million, 6.3% of revenue) and marketing to support new product development. The "CORE" program is expected to generate cost savings in gross profit through automation and vendor negotiations.

Outlook: The company anticipates continued growth in disposable sales but notes that equipment sales will remain lower as customers prefer the company's loan model. Full-year savings from the CORE program are expected to be partially offset by increases in other product costs.

Risks and Contingencies:

• Foreign Exchange: With 62% of revenue from international markets, the company is exposed to currency fluctuations. It utilizes forward contracts to hedge these risks.
• Regulatory and Market: Sales are susceptible to regulatory changes, market acceptance of new technologies, and competitive pricing.
• Acquisition Integration: The company recently completed the acquisition of Transfusion Technologies and is integrating its operations.

Investor Verification Checklist

• Accounting Adjustments: Verify the impact of the $2.3 million cumulative effect of accounting change (SFAS 133) on net income to assess core operating performance.
• Inventory Build: Review the $4.6 million increase in inventory to ensure it aligns with sales forecasts and does not indicate obsolescence risks.
• Equipment Strategy: Confirm the long-term financial impact of shifting from equipment sales to a loan model, specifically regarding capital expenditure requirements and revenue recognition timing.
• Goodwill Valuation: Note the $2.8 million write-down of goodwill related to the Transfusion Technologies acquisition due to tax valuation allowance adjustments.
• Debt Levels: Monitor the increase in total debt to $75.7 million and the company's ability to service this debt given the decline in operating cash flow.